译吧论坛
您当前的位置:主页 > 翻译资讯 > 译文欣赏 > 基因预测它莫西芬在乳腺癌治疗中的作用

基因预测它莫西芬在乳腺癌治疗中的作用

时间:2010-07-27 21:52    来源:    作者: 点击:
每日一句: ...[详情]
 

    A single gene variant predicts breast cancer survival after tamoxifen treatment, a new study finds.

    In the 46% of women with the "good" gene, tamoxifen works as well as newer drugs. For women with the gene variant linked to poor response to tamoxifen treatment, other treatment strategies would be a better choice.

    In the past 25 years, tamoxifen has prevented more than half a million deaths from breast cancer. The drug helps prevent breast cancer recurrence after surgery. Tamoxifen is still a useful drug, although newer drugs called aromatase inhibitors seem to work better in clinical trials.

    Now it appears that some women will do at least as well if they're treated with tamoxifen. Such women carry a version of a gene called CYP2D6 that makes tamoxifen work better.

    The gene encodes an enzyme crucial to tamoxifen activity. About 46% of women have a version of the gene that contributes to high enzyme activity. Others have genes that contribute to low or intermediate activity of the enzyme.

    Werner Schroth, PhD, of Germany's Fischer-Bosch Institute of Clinical Pharmacology, and colleagues analyzed CYP2D6 genes in 1,325 postmenopausal women treated with tamoxifen for early-stage breast cancer in Germany and in the U.S.

    They found that women with the highly active version of the gene were significantly less likely to have their breast cancer come back after five years of tamoxifen treatment. These women had outcomes similar to those seen in women treated with aromatase inhibitors.

    "[This] should provide new impetus to the medical and scientific community to revisit the issue of the relative efficacy of these two approaches in women with early breast cancer," Schroth and colleagues conclude.

    The researchers suggest that genetic testing could identify women who should not be treated with tamoxifen.

    最新发明剖明,单个基因变异体可以展望经由它莫西芬治疗后乳腺癌患者的存活情形。

    在46%携带该"好"基因的妇女中,它莫西芬与新药的治疗下场不异。携带该基因变异体的妇女,对它莫西芬治疗耐受,是以其他的治疗方案会更好。

    在已往的25年中,它莫西芬使赶过50万的患者免于作古于乳腺癌。该药物还制止术后乳腺癌的复发。是以它莫西芬仍旧是一个很是有效的药物,虽然新的芬芳酶按捺剂药物在临床试验上下场似乎更好。

    此刻看起来一些妇女用它莫西芬治疗的下场会很好。这些妇女携带有CYP2D6基因的一个变异体,该变异体使它莫西芬的浸染下场更好。

    该基因编码一个酶,这个酶在它莫西芬活阐扬历程中很是关键。约莫46%的妇女携带该基因的一种变异体,这种变异使该酶的活年夜年夜增强。而其他妇女携带的变异体的酶活性较低或中等。

    Werner Schroth是德国Fischer-Bosch临床药理研究所的博士。他和同事研究了1325例德国以及美国使用它莫西芬治疗早期乳腺癌的绝经后的妇女的CYP2D6基因。

    他们发明携带该基因高活性变异体的妇女在经由5年它莫西芬治疗后,乳腺癌复发率很低。其治疗下场与使用芬芳酶按捺剂治疗的妇女的治疗下场相似。

    Schroth及同事断定说:"这将给医学以及科学协会新的动力去评价这两种要领在治疗妇女早期乳腺癌的浸染。

    研究职员以为遗传检测可以确定哪些妇女应该用它莫西芬治疗。




扩展阅读: You never really hear the truth from your subordinates until after 10 in the evening. 晚上十点往后你才华从属下那里听到些真话。 Success is not defined by obtaining everything you want, but by appreciating everything you ha...[详情]